Dissertation · 2026 · Open access

Bispecific T cell engager therapy for refractory rheumatoid arthritis

Laura Bucci

Published 1 January 2026 · DOI 10.25593/open-fau-2793

Open PDFView at the publisherCite this paper

In brief

“Bispecific T cell engager therapy for refractory rheumatoid arthritis” is a 2026 dissertation by Laura Bucci. OpenAlex counts 0 citations as of 20 November 2026. It is open access: the full text is free to read.

Citations
0
References
26
Authors
1

Abstract

Bispecific T cell engagers (BiTEs) kill B cells by engaging T cells. BiTEs are highly effective in acute lymphoblastic leukemia. Here we treated six patients with multidrug-resistant rheumatoid arthritis (RA) with the CD19xCD3 BiTE blinatumomab under compassionate use. Low doses of blinatumomab led to B cell depletion and concomitant decrease of T cells, documenting their engager function. Treatment was safe, with brief increase in body temperature and acute phase proteins during first infusion but no signs of clinically relevant cytokine-release syndrome. Blinatumomab led to a rapid decline in RA clinical disease activity in all patients, improved synovitis in ultrasound and FAPI-PET-CT and reduced autoantibodies. High-dimensional flow cytometry analysis of B cells documented an immune reset with depletion of activated memory B cells, which were replaced by nonclass-switched IgD-positive naïve B cells. Together, these data suggest the feasibility and potential for BiTEs to treat RA. This approach warrants further exploration on other B-cell-mediated autoimmune diseases.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Bucci, L. (2026). Bispecific T cell engager therapy for refractory rheumatoid arthritis. https://doi.org/10.25593/open-fau-2793

MLA 9

Bucci, Laura. “Bispecific T cell engager therapy for refractory rheumatoid arthritis.” 2026. https://doi.org/10.25593/open-fau-2793.

Chicago

Bucci, Laura. 2026. “Bispecific T cell engager therapy for refractory rheumatoid arthritis.” https://doi.org/10.25593/open-fau-2793.

Harvard

Bucci, L. (2026) ‘Bispecific T cell engager therapy for refractory rheumatoid arthritis’. doi:10.25593/open-fau-2793.

IEEE

L. Bucci, “Bispecific T cell engager therapy for refractory rheumatoid arthritis,” 2026, doi: 10.25593/open-fau-2793.

BibTeX

@phdthesis{bucci2026bispecific,
  title     = {{Bispecific T cell engager therapy for refractory rheumatoid arthritis}},
  author    = {Bucci, Laura},
  year      = {2026},
  doi       = {10.25593/open-fau-2793},
  url       = {https://doi.org/10.25593/open-fau-2793}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • bispecific T-cell engagers
  • blinatumomab
  • rheumatoid arthritis
  • refractory arthritis
  • B-cell depletion
  • T cell depletion
  • immune reset
  • memory B cells

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Bucci, L. (2026). Bispecific T cell engager therapy for refractory rheumatoid arthritis. https://doi.org/10.25593/open-fau-2793

How many times has this paper been cited?

0 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: sign in and open the PDF from this page.

Who wrote this paper?

Laura Bucci.

What is the DOI of this paper?

10.25593/open-fau-2793, permanently at https://doi.org/10.25593/open-fau-2793. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.